FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OWIB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average b	urden									
	hours per response:	0.5									
- 1											

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Owen (Name and Address of Reporting Person* Dwen Catherine E. ast) (First) (Middle) /O AGIOS PHARMACEUTICALS, INC.				AC 3. E	2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 06/13/2024										eck all appli Directo	cable) or (give title	g Pers	on(s) to Issi 10% Ow Other (s below)	ner
88 SIDNEY STREET (Street) CAMBRIDGE MA 02139					4. If	Amer	ndmer	nt, Date	of O	Original F	iled	(Month/D	Line	Individual or Joint/Group Filing (Check Applicable ne) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(\$	State) ((Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											d to				
		Tab	le I - Non	-Deriv	ative	Sec	uriti	ies Ac	qu	ired, [Disp	osed o	of, o	r Ben	eficial	ly Owne	t			
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I					2A. Deeme Execution if any (Month/Day		ion Date	Code (In						Benefici	es Forrially (D) (Following (I) (II)		r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	v	Amount		(A) or (D)	Price	Transac	ransaction(s) Instr. 3 and 4)			(IIIsti. 4)
Common stock			06/13	3/2024					M		1,97	6	A \$0		1,	1,976		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Date,	Code (Inst				6. Date Exercisab Expiration Date (Month/Day/Year)			Amount		ount of urities erlying vative S		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title		Amount or Number of Shares					
Restricted stock units	(1)	06/13/2024			M			1,976		(2)	Γ	(2)	Com		1,976	\$0	3,953		D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Remarks:

/s/ William Cook, as attorneyin-fact for Catherine Owen ** Signature of Reporting Person

06/17/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.